Tandem Diabetes Care (NasdaqGM:TNDM) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsJoanne Wuensch - Managing DirectorJohn Sheridan - President and CEOJon Block - Managing DirectorLeigh Vosseller - EVP and CFOMathew Blackman - Managing DirectorMatt Taylor - Managing DirectorMike Kratky - Senior Managing Director of Medical Devices and Technology Equity ResearchShaymus Contorno - Equity Research AssociateSusan Morrison - EVP and Chief Administrative OfficerTravis Steed - Managing Dir ...

Financial Data and Key Metrics Changes - In 2025, Tandem achieved over $1 billion in worldwide sales, marking a 12% growth year-over-year, with U.S. sales increasing by 10% to $707 million and international sales growing by 15% to $308 million [17][19] - Q4 2025 saw record worldwide sales of $290 million, representing a 15% year-over-year growth, with U.S. Q4 sales increasing by 14% to $210 million [17][18] - Gross margin expanded by 3 percentage points to 54% for the full year, with the highest quarterly margin ever recorded at 58% [19][20] - Adjusted EBITDA was 11% of sales in Q4, a 10 percentage point improvement over the prior year, and the company reported its first positive operating margin since 2021 at 3% of sales in Q4 [20] Business Line Data and Key Metrics Changes - The U.S. saw more than 27,000 pump shipments in Q4, with renewals from loyal customers making up over half of the shipments [18] - Internationally, Q4 sales grew 17% year-over-year, delivering $80 million in sales and 11,000 pump shipments [19] Market Data and Key Metrics Changes - The company began direct commercial operations in the U.K., Switzerland, and Austria, with expectations for strong performance in these markets [9][27] - Direct sales represented approximately 5% of total international sales in 2025, expected to increase to about 15% in 2026 [28] Company Strategy and Development Direction - Tandem's strategy focuses on modernizing commercial operations, delivering new technology, and reshaping the business model to drive sustainable growth and profitability [8][13] - The company plans to accelerate pharmacy coverage for its products, transitioning to a pay-as-you-go reimbursement model to enhance customer access and reduce out-of-pocket costs [15][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term objectives of accelerated sales growth, with a gross margin target of at least 65% and an operating margin of 25% [21] - The transition to a pay-as-you-go model is expected to moderate 2026 sales growth but is seen as a key driver for long-term value creation [23][30] Other Important Information - The company plans to launch multiple new products in 2026, including Mobi Tubeless, which is expected to redefine pump wearability [11][12] - The anticipated revenue for 2026 is projected to be in the range of $730 million to $745 million, incorporating pricing headwinds due to the new business model [26] Q&A Session Summary Question: Can you provide context on the expected growth rates for U.S. and international shipments? - Management indicated that overall revenue growth for the year is expected to be in the range of 10%-11%, with double-digit growth in shipments and a return to growth in new shipments [35] Question: What is the current status of pharmacy coverage and contracting? - Management confirmed contracts with major PBMs covering about 80% of lives, with formulary access currently at roughly one-third of lives covered [40] Question: Why is now the right time to implement the pay-as-you-go model? - Management noted that experience gained in Q4 and positive discussions with payers made this the right time for the transition [44] Question: How will the transition to direct sales impact revenue growth? - Management explained that while there are near-term headwinds, the transition is expected to create long-term benefits and improve market access [49] Question: What are the key levers for margin expansion moving forward? - Management highlighted pricing strategies and product cost reduction initiatives as significant levers for improving margins [56]

Financial Data and Key Metrics Changes - In 2025, Tandem Diabetes Care achieved over $1 billion in worldwide sales, marking a 12% growth year-over-year, with U.S. sales increasing by 10% to $707 million and international sales growing by 15% to $308 million [13][16] - Q4 2025 saw record worldwide sales of $290 million, representing a 15% year-over-year growth, with U.S. sales increasing by 14% to $210 million [14][15] - Gross margin expanded by 3 percentage points to 54% for the full year, with the highest quarterly margin ever recorded at 58% in Q4 [16][17] - Adjusted EBITDA was 11% of sales in Q4, a 10 percentage point improvement over the prior year, and the company reported its first positive operating margin since 2021 at 3% of sales in Q4 [17] Business Line Data and Key Metrics Changes - The U.S. market saw more than 27,000 pump shipments in Q4, with renewals from loyal customers making up over half of the shipments [15] - Internationally, Q4 sales grew 17% year-over-year, delivering $80 million in sales and 11,000 pump shipments [16] - Sales through the pharmacy channel nearly doubled from Q3, growing to $16 million or 7% of total U.S. sales in Q4 [15] Market Data and Key Metrics Changes - The company began direct commercial operations in the UK, Switzerland, and Austria, with expectations for strong sales productivity in these markets [6][23] - Direct sales represented approximately 5% of total international sales in 2025, expected to increase to about 15% in 2026 [24] Company Strategy and Development Direction - The company is focused on three key initiatives: modernizing commercial operations, delivering new technology, and reshaping the business model [4][5] - The transition to a pay-as-you-go reimbursement model is expected to drive market growth and profitability, with plans to increase pharmacy coverage for both t:slim X2 and Mobi platforms [10][11] - The company aims to maintain leadership in automated insulin delivery (AID) systems and plans to begin a pivotal trial for a fully closed loop algorithm later this year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving long-term objectives of accelerated sales growth, with a gross margin target of at least 65% and an operating margin of 25% [18] - The transition to the pay-as-you-go model is anticipated to moderate sales growth in 2026 but is expected to create a more predictable revenue stream over time [19][21] - Management highlighted the importance of pump shipments as a key indicator of progress in growing the market while expanding margins [19] Other Important Information - The company exited 2025 with nearly $300 million in total cash and investments, generating free cash flow in both Q3 and Q4 [17] - The anticipated revenue headwinds from the pay-as-you-go model are expected to be most pronounced in 2026, with a projected U.S. sales range of $730 million to $745 million [22] Q&A Session Summary Question: Can you provide context on the expected growth rates for U.S. and international shipments? - Management indicated that overall revenue growth for the year is expected to be in the line of 10-11%, with double-digit growth in shipments [32] Question: What is the current status of pharmacy coverage and contracting? - Management confirmed contracts with major PBMs covering about 80% of lives, with formulary access currently at roughly a third [40] Question: Why is now the right time for the pay-as-you-go model? - Management stated that the experience gained in Q4 and positive conversations with payers made this the right time for the transition [44] Question: How will the transition to direct sales impact revenue? - Management explained that while there are headwinds from the transition, the long-term benefits of direct sales and pricing premiums are expected to outweigh these challenges [77] Question: What are the expected impacts of the pharmacy shift on the P&L? - Management noted that the headwinds from the pay-as-you-go model will be more pronounced in 2026, but the transition is expected to lead to significant revenue growth in subsequent years [68]

来源：滚动播报 据知情人士透露，强生酝酿出售其计划分拆的骨科业务部门，大型私募股权机构已开始关注潜在交易。 因讨论未公开消息而要求匿名的知情人士表示，名为DePuy Synthes的业务在出售时的估值可能超过200 亿美元。这些知情人士表示，强生在整理DePuy Synthes的相关文件和财务资料，以便在未来几周与潜 在买家会面。他们还称，多家大型私募股权公司正考虑联合收购该业务。 ...

Group 1 - The core viewpoint of the article is that despite perceptions of Japan's economic stagnation and aging population, global capital is increasingly attracted to Japan due to the undervaluation and quality of its assets, driven by a combination of currency depreciation and proactive government policies to invite foreign investment [1][3][5] - Japan's net overseas assets have reached a historical high of 533 trillion yen by the end of 2024, indicating that Japan has significant financial resources, but much of it is invested abroad rather than domestically [5] - The depreciation of the yen has made Japanese companies and assets cheaper for foreign investors, allowing them to acquire high-quality assets at lower prices, which is perceived as an opportunity rather than a sign of weakness [7][9] Group 2 - Three key changes expected around 2026 are driving foreign capital interest in Japan: a shift in monetary policy away from negative interest rates, a stabilization of the yen, and a push for corporate reform in Japan [9][11] - The Tokyo Stock Exchange has implemented regulations requiring underperforming companies to present improvement plans, which is prompting Japanese firms to innovate and seek foreign investment, creating new opportunities for capital [13][14] - Foreign capital is particularly interested in Japan's core assets that are difficult to replicate, such as essential technologies in semiconductor materials, as well as industries related to aging populations, including healthcare robots and medical devices [16][18] Group 3 - Prime urban land and infrastructure in major Japanese cities like Tokyo and Osaka are becoming increasingly valuable due to population density, despite an overall decline in Japan's population [20] - The article emphasizes the importance of maintaining currency stability for national wealth, contrasting Japan's situation with the stability of the Chinese yuan, which provides a safety net for ordinary citizens [22][24] - The global capital movement towards Japan serves as a reminder of the necessity for countries to strengthen their own technological capabilities and maintain control over their wealth to navigate the complexities of global investment [24]

业务进展情况 介入式脑机接口项目已完成技术验证，预计2026年启动首例人体临床试验，2028年提交注册申请，为神 经调控领域创新突破奠定基础。 经济观察网 心玮医疗-B（06609.HK）公布了2026年的经营目标及多项核心业务进展。 公司业绩目标 公司于2026年2月7日公布2026年经营目标，计划全年营收不低于5.4亿元、利润不低于1亿元，凸显对业 绩增长的信心。 产品研发进展 自主研发的自膨式颅内药物洗脱支架注册申请已于2026年1月获国家药监局受理，预计2026年底完成取 证，有望成为全球首款同类产品。同时，弹簧圈等产品预计2026年第一季度获得海外市场认证，加速国 际化布局。 战略推进 公司计划以2025年财务数据于2026年申报科创板上市，目前已进入上市辅导阶段，若成功落地将提升资 本平台流动性。 以上内容基于公开资料整理，不构成投资建议。 ...

业绩经营情况 经济观察网 微泰医疗-B的核心产品LinX持续葡萄糖监测系统（CGM）于2025年12月23日获得巴西上市 批准，适用于成人和儿童糖尿病患者。巴西是拉丁美洲核心市场，患病人数全球第六，糖尿病支出全球 第三，此次获批将推动公司2026年海外业务加速扩张。公司产品已进入欧洲多国医保体系，并销往全球 118个国家和地区，国际化布局有望持续深化。 以上内容基于公开资料整理，不构成投资建议。 产品研发进展 公司研发管线包括第二代Equil贴敷式胰岛素泵、混合闭环胰岛素输注系统及人工胰腺系统，其中儿童 适应症（3-17岁）已于2025年9月获中国药监局批准，将成为2026年增量来源。同时，公司通过内部AI 团队与科研院所合作，探索AI大模型在CGM领域的应用，推动"设备+算法+云平台"模式升级。 2025年"双十一"期间，公司CGM产品全网GMV增长218%，二代动态血糖仪出货量同比增长622.8%，新 用户数增长300%，线上渠道放量显著。中信建投证券指出，2026年CGM产品在国内将通过"电商+院 内"双渠道延续高增长，海外市场因基数小、医保准入扩大，收入增速预计保持高位。利润端，2025年 H1归母净 ...

Group 1 - Strong demand for green, smart, and healthy consumption during the Spring Festival holiday, with sales of smart wearable devices increasing by 130%, smart blood pressure monitors and blood glucose meters up over 60%, and organic food sales rising by 52% [1] - The U.S. Federal Reserve's January meeting minutes reveal significant divisions among decision-makers regarding future interest rate directions, with some members discussing the possibility of rate hikes if inflation remains above 2% [1] - High-profile political changes in Japan as Fumio Kishida is confirmed as the new Prime Minister, with expectations to focus on accelerating budget reviews and implementing the U.S.-Japan trade agreement [1] Group 2 - The Spring Festival holiday sees a booming market for holiday consumption and tourism services, with regulatory measures in place to stabilize prices in accommodation, dining, and other sectors [2] - Despite not being listed on the capital market, the founder of Lu Hua Group has been active in the A-share market, investing approximately 400 million yuan and 1 billion yuan in recent private placements [2] - The appointment of a "post-00" executive at Xiao Fang Pharmaceutical, with the nomination of a 24-year-old as a non-independent director, highlights a generational shift in corporate leadership [2] Group 3 - The China Real Estate Market Outlook report predicts a 6.2% year-on-year decline in new residential sales area in 2026, with a narrowing decline compared to 2025 [3] - Deloitte forecasts a 26% growth in the global semiconductor industry by 2026, reaching a record high of $975 billion, driven by the development of AI infrastructure [3] Group 4 - Barclays Bank reports that the AI and robotics market is expected to grow to a trillion-dollar scale by 2035, marking it as a key investment theme for the next decade [5] - UBS predicts that 2026 will be a critical turning point for humanoid robots, with global shipments expected to reach 30,000 units and the Chinese market surpassing 8.5 billion yuan [5] - The AI boom is driving unprecedented electricity demand, with gas turbine manufacturers experiencing a backlog of orders extending to 2030 [5] Group 5 - The global AI unicorn Anthropic anticipates paying $80 billion in sales shares to cloud service providers by 2029, a significant increase from $1.3 million in 2024 [7] - Bayer proposes a $7.25 billion settlement in the U.S. related to its flagship herbicide Roundup, addressing over 200,000 cancer-related lawsuits [7] - Volkswagen's marine engine and heat pump production division, Everllence, is attracting interest from top private equity firms, with a potential valuation between €5 billion and €6 billion [7]

经济观察网根据公开信息，登士柏西诺德(Dentsply Sirona)近期值得关注的事件主要围绕其2025年第三 季度业绩及战略调整。以下是基于最新可用资料的梳理： 业绩经营情况 公司于2025年11月10日发布2025年第三季度报告，净销售额为9.04亿美元(约合人民币63.39亿元)，同比 下降5.0%；录得净亏损4.27亿美元(约合人民币30.41亿元)，部分原因是商誉减值2.63亿美元。 战略推进 同期推出"重返增长"战略，聚焦客户体验、美国市场优化、员工赋能及运营效率提升，旨在扭转业绩下 滑趋势。 公司业绩目标 管理层在第三季度报告中预计2025年全年净销售额为36-37亿美元，调整后每股收益约1.60美元，这一 展望反映了公司对下半年改善的预期。 高管变动 2025年第二季度完成管理层交接，新任首席执行官Dan Scavilla于2025年8月1日正式履新，强调将投资 导向可持续增长领域。尽管此为历史事件，但新团队的执行效果可能持续影响2026年战略方向。 以上内容基于公开资料整理，不构成投资建议。 ...

凭借创新设计与技术实力，FattaLab®此前已斩获美国消费技术协会2026年国际消费电子展(CES)创新 奖，获得国际消费科技领域权威认可。 转自：扬子晚报 据了解，当前，代谢相关脂肪性肝病（MAFLD）已成为全球健康领域的重要挑战，其管理需求与日俱 增。传统检测方法主要依赖医院超声、CT或活检等手段，不仅流程相对繁琐，而且在可及性方面存在 明显不足，难以有效满足早期筛查与动态管理的实际需求。FattaLab®以家用化、无创化、定量化为核 心，实现"一次扫描、读懂肝健康"，与全球减重药物、体重管理、慢病干预趋势高度协同，为健康市场 提供精准检测入口，被视为打开脂肪肝管理赛道的"金铲子"。 扬子晚报网 2月18日讯（记者 姜婧仪 通讯员 江轩）近日，意领科技有限公司正式宣布，旗下FattaLab® 肝脏脂肪测量仪获得美国食品药品监督管理局（FDA）510(k)注册批准。作为全球首款轻量化肝脏脂肪 定量检测设备，此次获批标志着中国原创肝脏健康监测技术正式迈入国际消费医疗赛道，推动肝脏健康 管理进入精准、便捷、可及的3.0时代。依托南京江宁的全球超级工厂与产业化基地，FattaLab®将快速 实现规模化交付，服务 ...